- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.10. | Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect | ||
| 09.10. | CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug | ||
| 08.10. | US government pumps money toward in vivo cell therapy programs | ||
| 08.10. | TransCode rewrites future, securing $25M lifeline and phase 3 cancer vaccine | ||
| 08.10. | Arthrosi raises $153M, fueling dash toward phase 3 gout data in 2026 | ||
| 08.10. | Immunology biotech Nilo launches with $101M and mission to harness neural circuits | ||
| 08.10. | Sanofi's $110M radioligand therapy hits response rate goal in phase 2 tumor trial | ||
| 07.10. | After high-profile FDA exit, Peter Marks lands at Eli Lilly | ||
| 07.10. | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners | ||
| 07.10. | US government earmarks up to $48M for development of Kernal's mRNA CAR-T | ||
| 07.10. | GLD flexes muscle-wasting ambitions, launching Altagenics with an assist from Heligenics | ||
| 07.10. | James Wilson's GEMMABio launches new gene therapy biotech for 'ultra-orphan' diseases | ||
| 07.10. | MapLight illuminates $262M IPO plans to fund Cobenfy competitor | ||
| 07.10. | AstraZeneca's $1.3B bet yields second phase 3 blood pressure win, bolstering differentiation case | ||
| 07.10. | How do you get pharmaceutical treatments where they're needed most? | ||
| 06.10. | TCG Crossover hauls in $1.3B for third investment fund in four years | ||
| 06.10. | AstraZeneca, Algen Biotechnologies pen $555M AI pact for immunology targets | ||
| 06.10. | Skye's shares crater as CB1 blocker fails to reduce weight in phase 2 obesity study | ||
| 06.10. | Ignota buys Kronos' pipeline, igniting 2nd chance salvo to rescue shelved programs | ||
| 06.10. | AbbVie flags $2.7B R&D hit to brace investors for lower full-year profit | ||
| 03.10. | Q3 biopharma layoffs hold steady, setting 2025 up to break last year's high | ||
| 03.10. | Leader of NIH's National Institute of Allergy and Infectious Diseases fired in alleged whistleblower retaliation | ||
| 03.10. | 4 reasons why life sciences still fail women at the top, despite a female-majority workforce: report | ||
| 03.10. | Rocket aborts mission to get gene therapy approved by FDA for rare bone marrow disorder | ||
| 02.10. | After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .